Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
A man was given two years to live after a colon cancer diagnosis. Now he's healthy thanks to combination of medicine and the ...
Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...
Chemotherapy commonly damages the intestinal lining, a well-known side effect. But this injury does not remain confined to ...
Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) has been made available within NHS Scotland for the first line treatment of adult patients with mismatch repair deficient (dMMR) or ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
After training, the model achieved an accuracy of nearly 80% in predicting the occurrence of metastases and recurrence of colon cancer, a result far superior to existing tools. In addition, signatures ...
Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results